ATX-304 / O-304: Exercise Mimetic or Hype?
An oral pan-AMPK activator and mitochondrial uncoupler being called “the biggest thing since retatrutide.” The mechanism is real — but the human evidence is a single 2018 diabetes trial. Here's the honest picture.
How It Works
O-304 activates AMPK — the cellular energy sensor switched on by exercise and calorie restriction — by inhibiting the phosphatase PP2C. AMPK is a master regulator of glucose and fat metabolism (JCI Insight 2018; Chem Biol Interact 2025).
It also acts as a mitochondrial uncoupler, creating a metabolic demand that forces cells to burn more substrate — the real mechanism behind the “burn more energy” claim, so far demonstrated in cells, worms and mice (Commun Biol 2023; Chem Biol Interact 2025).
In diabetic mice O-304 drives skeletal muscle and heart to take up glucose without insulin, prevents glycogen build-up, and helps preserve β-cell function (Commun Biol 2023).
In aged mice it reproduced benefits of exercise — improved cardiac function and exercise capacity — which is why its developers call it an exercise mimetic. Still mouse data (Commun Biol 2021).
What the Data Shows
Key Takeaways
- O-304 (development name ATX-304) is an oral pan-AMPK activator and mitochondrial uncoupler developed by the Swedish biotech Betagenon/Amplifier Therapeutics (JCI Insight 2018; Commun Biol 2023).
- In its ONE human study — a 2018 Phase 2a proof-of-concept in type-2 diabetics on metformin — it lowered fasting glucose and HOMA-IR, improved microvascular perfusion, reduced blood pressure, and was well tolerated (JCI Insight 2018).
- In diabetic/obese mice it raises insulin-independent glucose uptake in muscle and heart and preserves β-cell function (Commun Biol 2023).
- In aged mice it behaved like an exercise mimetic, improving cardiac function and exercise capacity (Commun Biol 2021).
- In a mouse fatty-liver (MASLD) model, ATX-304 reduced body-fat mass and cholesterol and cut liver steatosis by increasing fat oxidation (JCI Insight 2025).
- It extended lifespan in C. elegans and showed anti-aging effects in cells, consistent with its uncoupler activity (Chem Biol Interact 2025).
- There is NO human weight-loss trial. Every fat-loss, muscle and longevity claim comes from mice, worms or cells — not people.
- It is NOT a GLP-1 and shares no mechanism with retatrutide; calling it “the biggest thing since retatrutide” pits one small 2018 glucose study against a compound with multiple large human weight-loss RCTs.
- Whether it “preserves muscle” in humans is untested — the muscle data is about glucose uptake in mouse muscle, not muscle retention during weight loss.
- Human effect size for fat loss, dosing, and long-term safety in people are all unknown.
- It is not an approved drug and is not sold by reputable peptide/research-chemical vendors — treat any “for sale” listing skeptically.
- Published human data has not visibly advanced past that single 2018 Phase 2a trial.
Frequently Asked Questions
What is O-304 (ATX-304)?
O-304 — clinical name ATX-304 — is an oral pan-AMPK activator and mitochondrial uncoupler developed by the Swedish biotech Betagenon/Amplifier Therapeutics. It activates AMPK, the cell’s energy sensor, mimicking some effects of exercise. Its only human data is a 2018 Phase 2a trial in type-2 diabetics.
Is O-304 / ATX-304 better than retatrutide for weight loss?
There is no head-to-head trial, and the comparison is a category error. Retatrutide is a GLP-1/GIP/glucagon triple agonist whose Phase 2 obesity RCT reported roughly 24% mean weight loss at the 12 mg dose over 48 weeks (Jastreboff et al., N Engl J Med 2023; PMID 37366315). O-304 is an AMPK activator with zero human weight-loss data — just one 2018 glucose study. The viral “biggest thing since retatrutide” framing is hype running ahead of the evidence.
Does O-304 make you burn more energy?
Mechanistically, yes — it is a mitochondrial uncoupler that raises metabolic demand, which is the basis of the “burn more energy” claim. But this has been shown in cells, worms and mice; no human study has demonstrated meaningful fat loss.
Does O-304 preserve muscle?
It boosts insulin-independent glucose uptake in mouse muscle and improved exercise capacity in aged mice, but “preserves muscle during weight loss” has never been tested in humans. Treat the muscle-sparing claim as an extrapolation, not an established fact.
Can I buy O-304 / ATX-304?
No — it is an investigational compound, not an approved medicine, and it is not sold by reputable peptide or research-chemical vendors. Any listing claiming to sell it should be treated with strong skepticism.
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Peer-Reviewed References
Educational purposes only. Not medical advice.
O-304 / ATX-304 is an investigational compound — not an approved medicine, and not sold by reputable vendors. Treat any “for sale” listing skeptically.
Every human claim here traces to a single 2018 Phase 2a trial; all other findings are from animal or cell studies and may not translate to people.